Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma.
作者信息
Cliff Edward R Scheffer, Reynolds Gemma, Popat Rakesh, Teh Benjamin W, Kesselheim Aaron S, Mohyuddin Ghulam Rehman
机构信息
Edward R. Scheffer Cliff, MBBS, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Gemma Reynolds, MChD, MIDI, National Center for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, Department of Infectious Diseases, Austin Health, Heidelberg, Melbourne, Victoria, Australia; Rakesh Popat, MBBS, PhD, NIHR UCLH Clinical Research Facility, University College London Hospitals, NHS Foundation Trust, London, United Kingdom; Benjamin W. Teh, MBBS, PhD, National Center for Infections in Cancer, Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia, Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia; Aaron S. Kesselheim, MD, JD, MPH, Program on Regulation, Therapeutics and Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and Ghulam Rehman Mohyuddin, MBBS, Division of Hematology and Hematological Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT.
出版信息
J Clin Oncol. 2023 Apr 1;41(10):1949-1951. doi: 10.1200/JCO.22.02197. Epub 2023 Jan 30.
Zotero 插件